Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naïve patients with type 2 diabetes.
OBJECTIVE
To evaluate the effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naïve patients with type 2 diabetes mellitus (T2DM).


METHODS
A randomized, double-blind, placebo-controlled, pilot-scale clinical trial was carried out in 24 patients with T2DM. Twelve subjects received thiamine orally (150 mg), once daily during a fasting state for 1 month. An additional 12 patients (control group) were given placebo for the same period of time. Before and after the intervention, fasting glucose, A1C, creatinine, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, very low-density lipoprotein, high-sensitive C-reactive protein, interleukin 6, tumor necrosis factor-alpha, leptin and adiponectin levels were estimated. Wilcoxon's signed-rank and Mann-Whitney U test were used for statistical analyses.


RESULTS
There were significant decreases in glucose (6.7 ± 1.0 mmol/l vs. 6.0 ± 1.0 mmol/l, p = 0.024) before and after the intervention, respectively, and leptin concentrations (32.9 ± 13.3 ng/ml vs. 26.9 ± 12.8 ng/ml, p = 0.027) before and after the intervention, respectively, with thiamine administration. There were no changes with the rest of the measurements.


CONCLUSIONS
Thiamine administration for 1 month decreased glucose and leptin concentrations in drug-naïve patients with T2DM.
González-Ortiz
Manuel
M
Cardiovascular Research Unit, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Colonia Independencia, Mexico. uiec@prodigy.net.mx
Martínez-Abundis
Esperanza
E
Robles-Cervantes
José A
JA
Ramírez-Ramírez
Viridiana
V
Ramos-Zavala
Maria G
MG
D000328:Adult; D000368:Aged; D015415:Biomarkers; D001786:Blood Glucose / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D016207:Cytokines / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007249:Inflammation / Q000378:metabolism; D008297:Male; D055442:Metabolome; D008875:Middle Aged; D010865:Pilot Projects; D013831:Thiamine / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D015415:Biomarkers; D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D016207:Cytokines; D007004:Hypoglycemic Agents; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D013831:Thiamine